Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 19Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Fallopian Tube Neoplasms 13Colorectal Neoplasms 11Pancreatic Neoplasms 9Carcinoma, Hepatocellular 8Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large B-Cell, Diffuse 5Prostatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sezary Syndrome 3Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Glioblastoma 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3

Interventions

Cisplatin 28Pemetrexed 24pembrolizumab 12Nivolumab 10Carboplatin 9atezolizumab 7Gemcitabine 7Cyclophosphamide 7durvalumab 6Drug Therapy 6sodium thiosulfate 5Radiotherapy, Intensity-Modulated 5tremelimumab 4aldesleukin 4Radiotherapy 4Interleukin-2 4sargramostim 3Vinorelbine 3Platinum 3Photochemotherapy 3Ipilimumab 3Doxorubicin 3Dihematoporphyrin Ether 3Chemotherapy, Adjuvant 3Cerebral Decortication 3vatalanib 2regorafenib 2niraparib 2lenvatinib 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma, Malignant × Disulfides × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡